Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 2
2011 3
2012 11
2013 7
2014 2
2015 5
2016 2
2017 5
2018 3
2019 2
2020 4
2021 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Approach to reduce the non-specific binding in microdialysis.
Nirogi R, Kandikere V, Bhyrapuneni G, Benade V, Saralaya R, Irappanavar S, Muddana N, Ajjala DR. Nirogi R, et al. Among authors: bhyrapuneni g. J Neurosci Methods. 2012 Aug 15;209(2):379-87. doi: 10.1016/j.jneumeth.2012.06.010. Epub 2012 Jun 23. J Neurosci Methods. 2012. PMID: 22732212
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders.
Nirogi R, Grandhi VR, Medapati RB, Ganuga N, Benade V, Gandipudi S, Manoharan A, Abraham R, Jayarajan P, Bhyrapuneni G, Shinde A, Badange RK, Subramanian R, Petlu S, Jasti V. Nirogi R, et al. Among authors: bhyrapuneni g. J Psychopharmacol. 2021 Jun;35(6):713-729. doi: 10.1177/0269881120986418. Epub 2021 Feb 5. J Psychopharmacol. 2021. PMID: 33546570
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
Nirogi R, Benade V, Daripelli S, Subramanian R, Kamuju V, Bhyrapuneni G, Muddana NR, Mekala VR, Petlu S, Jayarajan P, Badange R, Shinde A, Jasti V. Nirogi R, et al. Among authors: bhyrapuneni g. Psychopharmacology (Berl). 2021 Jun;238(6):1495-1511. doi: 10.1007/s00213-021-05779-x. Epub 2021 Feb 7. Psychopharmacology (Berl). 2021. PMID: 33550481
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
Nirogi R, Bhyrapuneni G, Muddana NR, Goyal VK, Pandey SK, Mohammed AR, Ravula J, Jetta S, Palacharla VRC. Nirogi R, et al. Among authors: bhyrapuneni g. Clin Drug Investig. 2021 May;41(5):469-482. doi: 10.1007/s40261-021-01027-4. Epub 2021 Mar 31. Clin Drug Investig. 2021. PMID: 33788154 Clinical Trial.
48 results